#hepatitis B

#NAIRHHA Day is now officially recognized by the federal government.

Nearly 70% of prior HBV vaccine nonresponders produced adequate antibodies after successful HCV treatment.

Hepatocellular carcinoma among people with HCV fell after the debut of direct-acting antivirals, but cases are rising for other groups.

However, researchers saw little difference across racial groups in HBV treatment initiation among those who were eligible.

Authors emphasize the need for increased hepatitis B vaccine awareness and education.

#NAIRHHADAY is now an officially recognized HIV awareness day. Join a September 14 webinar to learn why this matters.

Hepatitis A and B declined in 2021, but new hepatitis C cases have doubled since 2014.

The American Red Cross started screening all donors using a questionnaire to evaluate behavior-based risk. Folks on PrEP may not donate.

In 2022, fatty liver disease accounted for nearly a quarter of all liver cancer cases on the transplant waiting list.

Researchers are working on a cure for hepatitis B and a vaccine and long-acting antivirals for hepatitis C.

About 40% of people worldwide are not aware that viral hepatitis is a leading cause of liver cancer.

Viral hepatitis could kill more people than malaria, tuberculosis and HIV combined if trends continue.

The proposal improves on current Medicare coverage, which allows cost-sharing fees and mostly excludes long-acting PrEP.

Restoration of gut function and microbial diversity could lead to improvement of hepatic encephalopathy.

Cancer survivors make awesome advocates, and the summer 2023 issue of Cancer Health profiles several inspiring figures.

While hepatitis C remains a leading cause, cirrhosis is increasingly caused by fatty liver disease and alcohol use.